TTM
$4.21
YoY change
-206.9%
5Y CAGR
—
Peak year (2025)
$2.33
Latest annual
$2.33
EPS (Diluted) history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: $2.33
EPS (Diluted) growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: -206.9%
EPS (Diluted) history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| 2025 | $2.33 | -206.9% | +$4.51 | ||
| 2024 | −$2.18 | -38.1% | +$1.34 | ||
| 2023 | −$3.52 | -62.2% | +$5.78 | ||
| 2022 | −$9.30 | +29.2% | −$2.10 | ||
| 2021 | −$7.20 | -3.5% | +$0.26 | ||
| 2020 | −$7.46 | -8.0% | +$0.65 | ||
| 2019 | −$8.11 | +7.1% | −$0.54 | ||
| 2018 | −$7.57 | +39.7% | −$2.15 | ||
| 2017 | −$5.42 | +13.2% | −$0.63 | ||
| 2016 | −$4.79 | +38.8% | −$1.34 | ||
| 2015 | −$3.45 | -28.9% | +$1.40 | ||
| 2014 | −$4.85 | +234.5% | −$3.40 | ||
| 2013 | −$1.45 | -31.3% | +$0.66 | ||
| 2012 | −$2.11 | +55.1% | −$0.75 | ||
| 2011 | −$1.36 | +30.8% | −$0.32 | ||
| 2010 | −$1.04 | -8.8% | +$0.10 | ||
| 2009 | −$1.14 | +78.1% | −$0.50 | ||
| 2008 | −$0.64 | -71.0% | +$1.57 | ||
| 2007 | −$2.21 | +102.8% | −$1.12 | ||
| 2006 | −$1.09 | -44.4% | +$0.87 | ||
| 2005 | −$1.96 | -28.7% | +$0.79 | ||
| 2004 | −$2.75 | -89.6% | +$23.81 | ||
| 2003 | −$26.56 | +112.8% | −$14.08 | ||
| 2002 | −$12.48 | — | — |
- 2025$2.33-206.9%
- 2024−$2.18-38.1%
- 2023−$3.52-62.2%
- 2022−$9.30+29.2%
- 2021−$7.20-3.5%
- 2020−$7.46-8.0%
- 2019−$8.11+7.1%
- 2018−$7.57+39.7%
- 2017−$5.42+13.2%
- 2016−$4.79+38.8%
- 2015−$3.45-28.9%
- 2014−$4.85+234.5%
- 2013−$1.45-31.3%
- 2012−$2.11+55.1%
- 2011−$1.36+30.8%
- 2010−$1.04-8.8%
- 2009−$1.14+78.1%
- 2008−$0.64-71.0%
- 2007−$2.21+102.8%
- 2006−$1.09-44.4%
- 2005−$1.96-28.7%
- 2004−$2.75-89.6%
- 2003−$26.56+112.8%
- 2002−$12.48—
EPS (Diluted) values are taken from Alnylam Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current diluted EPS (TTM) is $4.21. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Alnylam Pharmaceuticals (ALNY) diluted EPS totalled $2.33 – plunged 206.9% year-over-year.
Across the available history, diluted EPS reached its high of $2.33 in 2025 and its low of −$26.56 in 2003.
Alnylam Pharmaceuticals EPS (Diluted) by Year
Alnylam Pharmaceuticals EPS (Diluted) 2025: $2.33
2025's diluted EPS for Alnylam Pharmaceuticals came in at $2.33, plunged 206.9% below 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals EPS (Diluted) 2024: −$2.18
Alnylam Pharmaceuticals posted diluted EPS of −$2.18 in 2024, plunged 38.1% below 2023.
Alnylam Pharmaceuticals EPS (Diluted) 2023: −$3.52
In 2023, Alnylam Pharmaceuticals reported diluted EPS of −$3.52, plunged 62.2% below 2022.
Alnylam Pharmaceuticals EPS (Diluted) 2022: −$9.30
Alnylam Pharmaceuticals diluted EPS in 2022 was −$9.30, grew 29.2% from 2021.
Alnylam Pharmaceuticals EPS (Diluted) 2021: −$7.20
Alnylam Pharmaceuticals diluted EPS in 2021 was −$7.20.
See more financial history for Alnylam Pharmaceuticals (ALNY). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest diluted EPS
| $22.95 | |
| $14.23 | |
| $13.23 | |
| $11.03 | |
| $7.28 | |
| $6.54 | |
| $3.59 | |
| $2.37 |
- $22.95
- $14.23
- $13.23
- $11.03
- $7.28
- $6.54
- $3.59
- $2.37
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation